Compare · BSX vs MDT
BSX vs MDT
Side-by-side comparison of Boston Scientific Corporation (BSX) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BSX focuses on Medical/Dental Instruments, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $116.11B, about 1.8x BSX ($65.10B).
- Over the past year, BSX is down 53.7% and MDT is down 4.0% - MDT leads by 49.6 points.
- MDT has been more active in the news (33 items in the past 4 weeks vs 3 for BSX).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- Medtronic plc.
- Price
- $44.93+2.74%
- $90.87-0.95%
- Market cap
- $65.10B
- $116.11B
- 1M return
- -10.82%
- -2.74%
- 1Y return
- -53.69%
- -4.04%
- Industry
- Medical/Dental Instruments
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 3
- 33
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest BSX
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
Latest MDT
- SEC Form 425 filed by Medtronic plc.
- SEC Form 425 filed by Medtronic plc.
- SEC Form 425 filed by Medtronic plc.
- SEC Form 425 filed by Medtronic plc.
- Amendment: SEC Form SC TO-I/A filed by Medtronic plc.
- Medtronic plc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 425 filed by Medtronic plc.
- EVP & President Cardiovascular Kiil Harry Skip sold $138,883 worth of Ordinary Shares (1,483 units at $93.65), decreasing direct ownership by 3% to 42,186 units (SEC Form 4)
- SEC Form 425 filed by Medtronic plc.
- SEC Form 425 filed by Medtronic plc.